RxSight, Inc.
RXST · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | -0.94 | 9.35 | 0.00 |
| FCF Yield | -1.12% | -0.92% | -0.37% | -0.02% |
| EV / EBITDA | -35.78 | -94.33 | -256.22 | -378.71 |
| Quality | ||||
| ROIC | -4.85% | -3.67% | -2.94% | -3.20% |
| Gross Margin | 74.89% | 74.76% | 71.59% | 55.54% |
| Cash Conversion Ratio | 0.12 | 0.37 | 1.08 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.65% | 32.87% | 40.14% | 45.20% |
| Free Cash Flow Growth | 37.14% | -84.20% | -1,027.37% | 91.95% |
| Safety | ||||
| Net Debt / EBITDA | 2.05 | 1.50 | 0.82 | 1.05 |
| Interest Coverage | -2,800.60 | -1,779.00 | -1,725.60 | -1,845.20 |
| Efficiency | ||||
| Inventory Turnover | 0.34 | 0.41 | 0.52 | 0.93 |
| Cash Conversion Cycle | 306.42 | 228.41 | 204.82 | 126.48 |